Back to search

Boston University

Evidence in support of probucol, an antioxidant, being the drug of choice in the treatment of atherosclerotic vascular disease

Abstract

dc:description.abstract

Atherosclerotic vascular disease (AVO) is a major contributing factor to our nation's leading cause of death, cardiovascular disease. Several mechanisms have been proposed in the genesis of AVO, one of the most persuasive being that the oxidized low density lipoprotein (LDL), not the native LDL, is the form recognized and taken up by intimal macrophages leading to the development of cholesterol-rich foam cells of atheranatous plaques. Probucol, an antioxidant, blocks the conversion of LDL to oxidized Probucol, an antioxidant, blocks the conversion LDL and slows the atherosclerotic process. After reviewing other mechanisms and treatments in AVO, the evidence , in my opinion, favors probucol as being the drug of choice in AVO managerrent.

Degree

thesis:*
Name thesis:degree_name
Master of Arts
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Biochemistry
Grantor dc:publisher
Boston University
Year dc:date.issued
1989

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Canavan, Diane M

Rights

dc:rights
Statement dc:rights
  • PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Dc Identifier Barcode
11719015075403
Dc Identifier Bibid
99187651460001161
Dc Identifier Other
b18374918

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Canavan, Diane M. Evidence in support of probucol, an antioxidant, being the drug of choice in the treatment of atherosclerotic vascular disease. masters thesis, Boston University, 1989. https://hdl.handle.net/2144/51550